KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 vs originator insulin degludec/insulin aspart in Chinese patients with type 2 diabetes inadequately controlled on basal or premixed insulin: A multicenter, randomized, open-label, phase 3 study.

Leili Gao, Zhifeng Cheng, Guoqing Ma, Xiaojun Cai, Xiaoyun Wang, Yibing Lu, Ziling Li, Wei Li, Shuping Zhao, Xuefeng Li, Chengwei Song, Yunming Gao, Jianlin Geng, Haiyan Cao, Jingfang Sun, Linong Ji

J Diabetes Investig 17(1) 42-50

PMID41269878
PMCIDPMC12757660
DOI10.1111/jdi.70175
发表日期2025-11-21
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:AI 判定为 flow diagram;Figure 2:非 KM 图。
摘要

摘要

AIMS: To compare the efficacy and safety of insulin degludec/insulin aspart biosimilar B01711 (HS-IDegAsp) with originator insulin degludec/insulin aspart-Ryzodeg (NN-IDegAsp) in Chinese patients with type 2 diabetes mellitus (T2DM) who were inadequately controlled on once- or twice-daily (BID) premixed or basal insulin ± oral antidiabetic drugs (OADs). MATERIALS AND METHODS: In this multicenter, randomized, open-label, parallel-group, active-controlled, phase 3 study, 367 participants with T2DM were randomized 1:1 to receive BID injections of HS-IDegAsp (n = 183) or NN-IDegAsp (n = 184) for 24 weeks. Insulins were administered subcutaneously with breakfast and the main evening meal at the same titration target. The primary endpoint was the change from baseline in glycated hemoglobin (HbA1c) to week 24. RESULTS: At Week 24, the least squares (LS) mean change in HbA1c from baseline was -1.12% (95% CI -1.24 to -1.01) and -1.23% (95% CI -1.34 to -1.11) with HS-IDegAsp and NN-IDegAsp, respectively. The LS mean difference (HS-IDegAsp minus NN-IDegAsp) at Week 24 was 0.10% (95% CI -0.06 to 0.27), demonstrating that HS-IDegAsp was non-inferior to NN-IDegAsp. There was no statistically significant difference (P > 0.05) in fasting plasma glucose or proportion of patients achieving HbA1c < 7.0% at Week 24 between both groups. Safety and immunogenicity were similar between both groups. CONCLUSIONS: HS-IDegAsp demonstrated comparable efficacy and safety to NN-IDegAsp during the 24-week treatment period in Chinese patients with inadequately controlled T2DM previously treated on once- or twice-daily premixed or basal insulin, with or without OADs.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Trial profile. AEs, adverse events; FAS, full analysis set; SAEs, serious adverse events; SS, safety analysis set.
非 KM Figure
Figure 2Changes in efficacy endpoints to week 24. (a) LS mean change from baseline in HbA 1c ; (b) Proportion of participants with HbA1c <7% and ≤6.5%; (c) Mean change from baseline in FPG; (d) Mean change from baseline in LAGE; (e) Mean change from baseline in PPGE; (f) Mean change from baseline in SDBG. FPG, fasting plasma glucose; HbA 1c , glycated hemoglobin; LAGE, largest amplitude of glycemic excursions; LOCF, last observation carried forward; LS, least squares; PPGE, postprandial glucose excursions; SD, standard deviation; SDBG, standard deviation of blood glucose.
非 KM Figure